About ObsEva
ObsEva is a company based in Geneve (Switzerland) founded in 2012. ObsEva has raised $94.7 million across 6 funding rounds from investors including Merck, New Leaf Venture Partners and Orbimed. ObsEva operates in a competitive market with competitors including Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma, among others.
- Headquarter Geneve, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Obseva Sa
-
Annual Revenue
$19.64 M (USD)-12as on Dec 31, 2022
-
Net Profit
-$29.88 M (USD)44as on Dec 31, 2022
-
EBITDA
-$15.68 M (USD)72as on Dec 31, 2022
-
Total Equity Funding
$94.7 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Merck
& 15 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ObsEva
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ObsEva
ObsEva has successfully raised a total of $94.7M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ObsEva
ObsEva has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, New Leaf Venture Partners and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked |
Investor details for ObsEva
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ObsEva
Investment portfolio details for ObsEva
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ObsEva
Detailed financials for ObsEva
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Obseva Comparisons
Peer comparison for ObsEva
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ObsEva
ObsEva operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sprout Pharmaceuticals, Hope Medicine, Rejoni, Gameto and Forendo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for hypoactive sexual desire disorder in women are developed.
|
|
| Locked | Locked | Locked |
Monoclonal antibodies are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for women's health conditions are developed using innovative hydrogels.
|
|
| Locked | Locked | Locked |
Therapeutics for fertility and menopause treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for reproductive health are developed.
|
Detailed competitors of ObsEva
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Obseva
Complete news archive for ObsEva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ObsEva
ObsEva was founded in 2012 and raised its 1st funding round 1 year after it was founded.
ObsEva is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
ObsEva is a funded company, having raised a total of $94.7M across 6 funding rounds to date.
Annual revenue of ObsEva is $19.64M as on Dec 31, 2022.
Developer of therapeutics for womens reproductive health and pregnancy. Its lead candidate is Linzagolix an orally active gonadotropin-releasing hormone and receptor antagonist for Fibroids and Endometriosis. It also has two receptor antagonists Ebopiprant and Nolasiban for preterm labor.
ObsEva's top competitors include Sprout Pharmaceuticals, Rejoni and Hope Medicine.
ObsEva has 16 investors. Key investors include Merck, New Leaf Venture Partners, Orbimed, Oxford Finance, and HBM Healthcare Investments.